Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.47 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724726 | 0.91 | CNR2 (0.50) | CNR2ATRPIK3CBPDE10ATDO2 | |
| SCHEMBL722381 | 0.89 | PRKDC (0.47) | P4HTMPRKDCATRATRIPPIK3CA | |
| SCHEMBL721427 | 0.83 | RET (0.49) | CNR2ATRATRIPLRRK2PDE10A | |
| SCHEMBL723929 | 0.78 | PIM1 (0.50) | — | |
| SCHEMBL4883336 | 0.78 | KDM4E (0.57) | CNR2ATRPIK3CAPIK3CBPIK3CG | |
| SCHEMBL723388 | 0.77 | KDM4E (0.51) | PRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL15173334 | 0.74 | TBK1 (0.67) | — | |
| SCHEMBL723758 | 0.74 | DYRK1A (0.47) | PIK3CALRRK2 | |
| SCHEMBL723599 | 0.72 | PIK3CA (0.43) | PIK3CA | |
| SCHEMBL725108 | 0.71 | KDR (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | CNR2 2678/4885P4HTM 2912/4885PRKDC 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.